Dual Mechanisms of HNO Generation
A R T I C L E S
Scheme 1. Structures of the Two Related, Spontaneously
HNO-Generating Salts, Angeli’s Salt and IPA/NO (1)
the related compound IPA/NO (1, the sodium salt of diazeni-
umdiolated isopropylamine; Scheme 1) has been shown to
34
mimic the chemical and biological properties of Angeli’s salt.
Unfortunately, neither of these salts is itself ideal from the drug
development perspective, as they are prone to deterioration on
storage and they are difficult to purify. Additionally, their similar
half-lives of ∼2 min for spontaneous hydrolysis at physiological
pH and temperature do not allow for prolonged exposure of
target tissues.
A possible approach to circumventing the limitations but
harnessing the advantages of such ions is to alkylate the salts
to produce stable neutral species that can be rigorously purified
and repurified as necessary, then induced to release HNO by
way of enzymatic, hydrolytic, or other tunable activation
pathways. To our knowledge, alkylating or otherwise suitably
derivatizing Angeli’s salt has been unsuccessful to date. In
compounds capable of serving as caged HNO donors, or
1
-5,20,21,25-33
prodrugs.
We are among those working to
develop a platform for systematically generating reliable,
controlled fluxes of HNO at programmable rates in physi-
ological media.
Historically, Angeli’s salt (Scheme 1) has been the reagent
3
1
of choice for generating HNO in aqueous solution. Recently,
35
contrast, 1 has proven amenable to alkylation. Here, we report
that acetoxymethylation of 1 as shown in eq 2 leads to prodrug
(
6) Wink, D. A.; Miranda, K. M.; Katori, T.; Mancardi, D.; Thomas, D. D.;
Ridnour, L.; Espey, M. G.; Feelisch, M.; Colton, C. A.; Fukuto, J. M.;
Pagliaro, P.; Kass, D. A.; Paolocci, N. Am. J. Physiol.: Heart Circ.
Physiol. 2003, 285, H2264–H2276.
2
(AcOM-IPA/NO), which is easily purifiable by column
chromatography and functions as an advantageous HNO donor
with an unexpected mechanism of activation.
(
(
7) Feelisch, M. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4978–4980.
8) Miranda, K. M.; Paolocci, N.; Katori, T.; Thomas, D. D.; Ford, E.;
Bartberger, M. D.; Espey, M. G.; Kass, D. A.; Feelisch, M.; Fukuto,
J. M.; Wink, D. A. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 9196–
9
201.
(
9) Paolocci, N.; Katori, T.; Champion, H. C.; St. John, M. E.; Miranda,
K. M.; Fukuto, J. M.; Wink, D. A.; Kass, D. A. Proc. Natl. Acad. Sci.
U.S.A. 2003, 100, 5537–5542.
(
(
10) Cheong, E.; Tumbev, V.; Abramson, J.; Salama, G.; Stoyanovsky,
D. A. Cell Calcium 2005, 37, 87–96.
11) Miranda, K. M.; Ridnour, L.; Espey, M.; Citrin, D.; Thomas, D.;
Mancardi, D.; Donzelli, S.; Wink, D. A.; Katori, T.; Tocchetti, C. G.;
Ferlito, M.; Paolocci, N.; Fukuto, J. M. Prog. Inorg. Chem. 2005, 54,
Results and Discussion
Compound 2 Hydrolyzes to HNO More Slowly and Ef-
ficiently than 1. A key goal of this research is to introduce an
array of agents that display a broad range of half-lives for HNO
release while minimizing the simultaneous generation of NO that
accompanies the spontaneous dissociation of salt 1 at physiological
pH. Ideally, this would come in the form of a series of water-
soluble compounds that produce reliable fluxes of pure HNO at
rates that are tunable for any given experimental application.
Compound 2 appears to represent a step in that direction.
3
49–384.
(
(
12) Miranda, K. M. Coord. Chem. ReV. 2005, 249, 433–455.
13) Paolocci, N.; Jackson, M. I.; Lopez, B. E.; Miranda, K.; Tocchetti,
C. G.; Wink, D. A.; Hobbs, A. J.; Fukuto, J. M. Pharmacol. Ther.
2
007, 113, 442–458.
(
(
(
(
(
(
(
(
14) S a´ enz, D. A.; Bari, S. E.; Salido, E.; Chianelli, M.; Rosenstein, R. E.
Neurochem. Int. 2007, 51, 424–432.
15) Landino, L. M.; Koumas, M. T.; Mason, C. E.; Alston, J. A. Chem.
Res. Toxicol. 2007, 20, 1693–1700.
16) Favaloro, J. L.; Kemp-Harper, B. K. CardioVasc. Res. 2007, 73, 587–
5
96.
17) Irvine, J. C.; Favaloro, J. L.; Widdop, R. E.; Kemp-Harper, B. K.
Hypertension 2007, 49, 885–892.
Under physiological conditions, Angeli’s salt is primarily an
HNO donor (<0.1% NO in the presence of a metal chelator
18) Fukuto, J. M.; Jackson, M. I.; Kaludercic, N.; Paolocci, N. Methods
Enzymol. 2008, 440, 411–431.
36
such as 50 µM diethylenetriaminepentaacetic acid (DTPA)).
3
4
In contrast, 1 generates mixtures of NO and HNO. Although
19) Lancel, S.; Zhang, J.; Evangelista, A.; Trucillo, M. P.; Tong, X.; Siwik,
D. A.; Cohen, R. A.; Colucci, W. S. Circ. Res. 2009, 104, 720–723.
20) Reisz, J. A.; Bechtold, E.; King, S. B. Dalton Trans. 2010, 39, 5203–
1 decomposes with nearly the same half-life as Angeli’s salt
37
(
1
2.3 min in pH 7.4 phosphate buffer at 37 °C), conversion of
5
212.
to 2 increased the half-life to 41 min (pH 7.4, 37 °C), which
21) Kovacic, P.; Edwards, C. L. J. Recept. Signal Transduct. [Early
Online]. DOI: 10.3109/10799893.2010.497152. Published online: Jun
offers a useful addition to the otherwise short half-lives available
for spontaneous generation of HNO in aqueous media.
The methods available to detect NO are quite varied and
adaptable, but quantitative analysis of HNO is limited by its
3
0, 2010.
(
(
22) Smith, P. A. S.; Hein, G. E. J. Am. Chem. Soc. 1960, 82, 5731–5740.
23) Kohout, F. C.; Lampe, F. W. J. Am. Chem. Soc. 1965, 87, 5795–
5
796.
(
24) Shafirovich, V.; Lymar, S. V. Proc. Natl. Acad. Sci. U.S.A. 2002, 99,
2
rapid and irreversible conversion to N O (eq 1). The most
7
340–7345.
common method for identifying HNO and establishing a lower
limit for the amount formed from a given donor is to trap HNO
(
(
25) Ware, R. W., Jr.; King, S. B. J. Org. Chem. 2000, 65, 8725–8729.
26) Zeng, B. B.; Huang, J.; Wright, M. W.; King, S. B. Bioorg. Med.
Chem. Lett. 2004, 14, 5565–5568.
38,39
with metmyoglobin (metMb)
according to eq 3. This method
(
(
27) King, S. B. Free Radical Biol. Med. 2004, 37, 735–736.
was used earlier to suggest that 1 is a donor of both NO and
28) Huang, J.; Kim-Shapiro, D. B.; King, S. B. J. Med. Chem. 2004, 47,
3
495–3501.
(
(
29) King, S. B. Curr. Top. Med. Chem. 2005, 5, 665–673.
(34) Miranda, K. M.; et al. J. Med. Chem. 2005, 48, 8220–8228.
(35) Saavedra, J. E.; Bohle, D. S.; Smith, K. N.; George, C.; Deschamps,
J. R.; Parrish, D.; Ivanic, J.; Wang, Y.-N.; Citro, M. L.; Keefer, L. K.
J. Am. Chem. Soc. 2004, 126, 12880–12887.
30) Pennington, R. L.; Sha, X.; King, S. B. Bioorg. Med. Chem. Lett.
2
005, 15, 2331–2334.
(
(
(
31) Miranda, K. M.; Nagasawa, H. T.; Toscano, J. P. Curr. Top. Med.
Chem. 2005, 5, 649–664.
(36) Lopez, B. E.; Shinyashiki, M.; Han, T. H.; Fukuto, J. M. Free Radical
Biol. Med. 2007, 42, 482–491.
32) Sha, X.; Isbell, T. S.; Patel, R. P.; Day, C. S.; King, S. B. J. Am.
Chem. Soc. 2006, 128, 9687–9692.
(37) Maragos, C. M.; Morley, D.; Wink, D. A.; Dunams, T. M.; Saavedra,
J. E.; Hoffman, A.; Bove, A. A.; Isaac, L.; Hrabie, J. A.; Keefer, L. K.
J. Med. Chem. 1991, 34, 3242–3247.
33) Kirsch, M.; B u¨ scher, A. M.; Aker, S.; Schulz, R.; de Groot, H. Org.
Biomol. Chem. 2009, 7, 1954–1962.
J. AM. CHEM. SOC. 9 VOL. 132, NO. 46, 2010 16527